Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05508009 · ClinicalTrials.gov registry record · Phase 1

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

A Phase 1 study of Cystinosis and FSGS, sponsored by Alice Bertaina.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT05508009: Recruiting Phase 1 study of Cystinosis and FSGS, sponsored by Alice Bertaina.

NCT05508009 is a Phase 1 study of Cystinosis and FSGS that is actively recruiting participants, run by Alice Bertaina. The registered enrollment target is 12 participants, below the 202-participant average among 4 other Cystinosis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05508009, a Phase 1 study of Cystinosis and FSGS, is actively recruiting participants, sponsored by Alice Bertaina.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT immunosuppression, to abrogate the need for lifelong immunosuppression, the risk of chronic rejection and, ultimately, the need for repeated transplantation.

Primary Outcome

Donor chimerism equal or greater to 95% after successful HSCT/KT therapy allows for withdrawal of immunosuppressive therapy in patient

Interventions

  • DRUG Fludarabine
  • RADIATION Total Body Irradiation
  • DRUG ATG
  • DRUG Cyclophosphamide 1200 mg/Kg
  • DRUG Cyclophosphamide 100 mg/Kg

Study Locations (1)

California

  • Lucile Packard Children's Hospital - Palo Alto

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2023-01-10
Est. Completion 2034-10
Phase Phase 1
Alice Bertaina

2 total trials

What NCT05508009 shows while recruiting

NCT05508009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 202-participant average among 4 other Cystinosis trials with a reported enrollment target (94% lower).

The record links to 5 conditions, with Cystinosis appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.

NCT05508009 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05508009 about?

NCT05508009 is a clinical study titled "Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor". This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT immunosuppression, to abrogate the need for lifelong immunosuppression, the...

What is the current status of trial NCT05508009?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-01-10. Estimated completion is 2034-10.

What conditions does trial NCT05508009 study?

This clinical trial studies the following conditions: Cystinosis, FSGS, SLE Nephritis, SIOD, CKD Stage 4.

What interventions are being tested in trial NCT05508009?

The interventions under investigation include: Fludarabine (DRUG), Total Body Irradiation (RADIATION), ATG (DRUG), Cyclophosphamide 1200 mg/Kg (DRUG), Cyclophosphamide 100 mg/Kg (DRUG).

Who is sponsoring clinical trial NCT05508009?

This trial is sponsored by Alice Bertaina, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05508009 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystinosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05508009, the US trial registry maintained by the National Library of Medicine. NCT05508009 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.